2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 706

Excess Mortality From Atherosclerotic Cardiovascular Disease in Systemic Sclerosis Compared to Lupus and Rheumatoid Arthritis
Abstract Number: 2399

Exercise On Prescription: Barriers to Participation in Community Based Exercise Programmes
Abstract Number: 221

Expanding the Clinical and Serological Spectrum of MDA5-Associated Dermatomyositis
Abstract Number: 1772

Expansion of Autoreactive Unresponsive CD21^-/Low B Cells in Sjögren’s Syndrome Associated Lymphoproliferation
Abstract Number: 1462

Expert Consensus for Performing Right Heart Catheterization in Suspicion of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Delphi Consensus Study with Cluster Analysis From the Eposs Group
Abstract Number: 2605

Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients
Abstract Number: 815

Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Abstract Number: 1722

Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Abstract Number: 2635

Exploring the Influence of Patient Perceptions On Medication Escalation in Daily Practice
Abstract Number: 1851

Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis
Abstract Number: 2506

Expression of Helios Facilitates Distinction Between FoxP3⁺ Treg and FoxP3⁺ Activated T Conventional Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 1944

Expression of Human Leukocyte Antigen-G in Polymyositis or Dermatomyositis
Abstract Number: 507

Expression of Micrornas (miRNAs) Predicted to Target Ro/SSA and La/SSB Autoantigens in Sjögren’s Syndrome (SS)
Abstract Number: 1759

Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abstract Number: 688

Expression of the Mer Receptor Tyrosine Kinase On Peripheral Blood Mononuclear Cells From Systemic Lupus Erythematosus Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].